12:00 AM
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cubist, Heptares deal

Heptares and Cubist partnered to discover and develop compounds against two undisclosed GPCR targets selected by Cubist. For the first target, Heptares will receive $5.5 million up front and up to about...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >